WS11.5 Newborn screening for cystic fibrosis in Norway

Lundman, Emma; Gaup, H.J.; Bjørnæs, A.M.; Storrøsten, Olav Trond; Rootwelt, Terje; Pettersen, Rolf D.

doi:10.1016/s1569-1993(14)60074-6

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21,22 Removal of p.Arg117His cannot be extrapolated to countries in which the polypirimidine variant in intron 8 in cis is on a T5 background, due to its associated pathogenicity. Recently, Norway 23 introduced NBS for CF with a mutation panel immediately excluding p.Arg117His T7, and The Netherlands removed it in July 2016.…”

Section: Discussionmentioning

confidence: 99%

Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process

et al. 2017

View full text Add to dashboard Cite

ObjectivesTo evaluate the French cystic fibrosis newborn screening algorithm, based on data tracked by a centralized monitoring process, from 2002 to 2014. The programme aimed to attain European Standards in terms of positive predictive value, sensitivity, the ratio of screen positive patients diagnosed with cystic fibrosis to infants who screen positive but with inconclusive diagnosis (CFSPID), and time to diagnosis.MethodsRetrospective analysis of programme performance, compliance with the algorithm, and changes in screening strategy.ResultsModifications in the flow chart protocol improved the positive predictive value to 0.31 while maintaining the sensitivity at 0.95. Among infants diagnosed with cystic fibrosis, or identified as CFSPID, sweat test results were obtained for 94%, and two mutations were identified after exhaustive screening for the gene, when applicable, in 99.6%. The rate of pending diagnosis was very low (0.5%). The ratio of infants with cystic fibrosis:CFSPID was 6.3:1. Age at initial visit at the CF centre was ≤ 35 days, respectively, in 53%/26%.ConclusionPerformances were in agreement with European standards, but timeliness of initial visit needed improvement. Our data complement an accumulating body of evidence demonstrating that attention must be paid to such ethical considerations as limiting carrier detection and inconclusive diagnosis. Newborn screening programmes should have a rigorous centralized monitoring process to warrant adjustments for improving performance to attain consensus guidelines.

show abstract

Section: Discussionmentioning

confidence: 99%